Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: dose response and induction of protective humoral responses in rats.
An attenuated, recombinant Salmonella typhimurium mutant, chi 4072(pYA2905), expressing the surface protein antigen A (SpaA) of Streptococcus sobrinus was investigated for its effectiveness in inducing protective immune responses against S. sobrinus-induced dental caries in an experimental caries model. Fischer rats were orally immunized with either 10(8) or 10(9) CFU of S. typhimurium chi 4072(pYA2905). Persistence of salmonellae in Peyer's patches and spleens and the induction of immune responses were determined. Maximum numbers of salmonellae were recovered from Peyer's patches of rats within the first week of immunization, with higher numbers recovered from rats given 10(9) CFU than from those given 10(8) CFU. Serum anti-Salmonella and anti-SpaA responses increased more rapidly in rats given 10(9) CFU than in rats given 10(8) CFU. The salivary antibody response to SpaA increased with time, but the response varied in the two groups. In a separate study, rats were orally immunized with the recombinant Salmonella mutant and then challenged with cariogenic S. sobrinus 6715. The levels of serum and salivary antibody and caries activity were assessed at the termination of the experiment. Higher levels of salivary immunoglobulin A antibody to SpaA and Salmonella carrier were detected in rats given 10(9) CFU than in those given 10(8) CFU, and these responses were higher than those in nonimmunized controls. Mandibular molars from immunized rats had lower numbers of recoverable streptococci and less extensive carious lesions than those from nonimmunized, control rats. These data indicate that oral immunization with an attenuated recombinant S. typhimurium expressing SpaA of S. sobrinus induces the production of antigen-specific mucosal antibody and confers protection against dental caries.
Redman
T K
TK
Department of Microbiology, University of Alabama at Birmingham 35294, USA.
Harmon
C C
CC
Lallone
R L
RL
Michalek
S M
SM
D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D003731:Dental Caries / Q000276:immunology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005856:Germ-Free Life; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D008562:Membrane Glycoproteins; D010581:Peyer's Patches / Q000382:microbiology; D051381:Rats; D011916:Rats, Inbred F344; D012463:Saliva / Q000276:immunology; D012486:Salmonella typhimurium / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000382:microbiology; D013290:Streptococcal Infections / Q000517:prevention & control*; D016986:Streptococcus sobrinus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D007071:Immunoglobulin A, Secretory; D008562:Membrane Glycoproteins; C055764:S-layer proteins; D014614:Vaccines, Synthetic